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Monovalent maleimide functionalization of gold
nanoparticles via copper-free click chemistry†
D. J. Nieves,a N. S. Azmi,ab R. Xu,ac R. Le´vy,a E. A. Yatesa and D. G. Fernig*a
A single maleimide was installed onto the self-assembled mono-
layer of gold nanoparticles by copper-free click chemistry. Simple
covalent biofunctionalisation is demonstrated by coupling fibro-
blast growth factor 2 and an oligosaccharide in a 1 : 1 stoichiometry
by thiol-Michael addition.
Gold nanoparticles have been used in biology for several
decades as a contrast agent in immunoelectron microscopy.
In these early applications, antibodies were adsorbed to the
nanoparticle surface.1,2 More recently, advances in passivation
of nanoparticle surfaces with small hydrophilic ligands have
provided the means to conjugate proteins and peptides to
nanoparticles stoichiometrically.3–6 Allied to new techniques
in optical microscopy,7–9 highly sensitive analysis of biological
interactions in living cells has been achieved, providing new
insights into biological processes.5,10,11
An important challenge for single molecule microscopies is
control over the stoichiometry of the biomolecule to the nano-
particle. Lack of such control can confound or alter the observed
biological behaviour due to multivalency12 or exchange.13 Stoichio-
metric coupling of proteins to gold nanoparticles has been
achieved through genetically encoded aﬃnity tags,3,6 electrostatic
charge14 and biomolecular recognition,15 among others.16 These
approaches, although leading to a stable conjugate, are non-covalent.
Thus, there remains the concern that the conjugated protein will
exchange and, therefore, alter the biological functionality of the
nanoparticle.13 Moreover, only some proteins and biomolecules
can be conjugated in this way, as others, e.g., polysaccharides
and nucleic acids, may require a quite diﬀerent conjugation
route. Therefore, an approach that allowed a chemically versatile
stoichiometric covalent linkage to be formed between biological
molecule and nanoparticle, in a structurally defined position,
would be of great interest.
Covalent linkage between nanoparticles and biomole-
cules has been demonstrated via diverse chemical routes
including those that are bioorthogonal (i.e., chemistry that
can occur within biological settings without interfering with
endogenous biochemistry). One such approach is the function-
alisation of nanomaterials with azide groups that serve as a
platform for reactions with strained cyclooctynes via both
copper-catalysed and copper-free click chemistry.17–20 Particu-
larly in the cases of copper-free methods, this was essential
to avoid the unfavourable consequences a copper catalyst
can have on biological systems through Fenton reactions.21,22
However, although some control over the number of reactive
groups present has been demonstrated,20 monovalency has
not. As monovalency is especially pertinent in the fields of
single molecule biophysics and biology, then a route to
provide control over number of labels per biomolecule is
highly desired.3,12,23
A maleimide is an attractive functional group for the
covalent labelling of biomolecules, due to its stability in water
(cf., N-hydroxysuccinimide, commonly used to react with
amines). The maleimide has a double bond, which will react
readily with thiols to form a covalent thioether linkage, known
as thiol-Michael addition.24,25 Thiols are present on the side
chain of cysteine residues in proteins, but are relatively scarce.
Moreover, the thiol group of cysteine, unless involved in a
catalytic site, can often be replaced by the hydroxyl group of
serine, with no discernable biological consequences, e.g., in
FGF2.26 This allows a single free thiol to be engineered in a
protein at a defined site, e.g., N-terminus. Thiols may also be
installed specifically on nucleic acids and polysaccharides.27,28
Thus, a maleimide functionalised nanoparticle is potentially a
very versatile tool.
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Here we describe the indirect installation of a maleimide
group on a nanoparticle via copper-free click chemistry. Gold
nanoparticles with azide function were generated by the incor-
poration of a small percentage of an azide functionalised
alkane-thiol ethylene glycol ligand into a self-assembled mono-
layer (SAM) of a mixture of peptidol and alkane-thiol ethylene
glycol ligands (structures of all ligands are presented in Fig. S1,
ESI†). The constituents of the monolayer, referred to as a ‘mix
matrix’, and the rationale for the ligand proportions have been
described previously and shown to impart very high stability to
the nanoparticles, including resistance to ligand exchange and
to non-specific binding in living cells.3,11 Upon addition of the
azide ligand, the other constituent ligands are proportionally
scaled to allow for the percentage of functional ligand in the
ligand mix. Hence, the ligand mix consisted of 99% (mol/mol)
of 2 mMmix-matrix ligands (70 : 30, CVVVT-ol to HS-C11-EG4-OH)
supplemented with 1% (mol/mol) azide ligand (HS-C11-EG5-N3).
One tenth volume of phosphate-buﬀered saline (10 PBS: 1.4 M
NaCl, 27 mM KCl, 81 mM Na2PO4, 12 mM KH2PO4, pH 7.4)
supplemented with Tween-20 0.1% (v/v) was added as buﬀer after
the addition of matrix ligands, to provide electrolytes to drive self-
assembly of the monolayer, then left overnight with mixing on a
rotary wheel. Excess free ligand was then removed from the
nanoparticles by Sephadex G-25 size-exclusion chromatography
with 1 Tris-buﬀered saline (20 mM Tris, 150 mM NaCl, pH 7.6)
with Tween-20 0.05% (v/v) (TBST0.05%) as the mobile phase. TBS is
the recommended buﬀer for the reaction with the dibenzo-
cyclooctyne functionalised with a maleimide group (Click-ITs
Maleimide DIBO Alkyne, Life Technologies, UK).
To evaluate the eﬀect of the azide ligand on the resistance of
the particles to ligand exchange, following size-exclusion chro-
matography on Sephadex G-25, the azide functionalised gold
nanoparticles (N3NPs) were subjected to a DTT ligand-exchange
assay, as previously described.29 The UV-vis absorption spec-
trum for the reaction was recorded at various time intervals and
the stability parameter calculated (Fig. S2, ESI†). The stability of
the nanoparticles containing azide ligand in the SAM was
identical to that of nanoparticles possessing a SAM of only
mix-matrix ligands. Both are resistant to ligand exchange in the
presence of 10 mM DTT for up to 48 h (Fig. S2a and b, ESI†). At
higher concentrations of DTT, i.e., 25 and 50 mM, nanoparticle
aggregation was observed after 24 h, since the stability para-
meter increased, which indicated that the monolayer was
undergoing ligand exchange. This is consistent with the pre-
viously reported stability to ligand exchange of nanoparticles
stabilised by such SAMs.29,30
The N3NPs were then used for a copper-free click reaction
with 20 mM of maleimide functionalised cyclooctyne (DIBO-Mal)
for one hour in the dark with mixing on a rotating wheel to yield
maleimide functionalised gold nanoparticles (Fig. S3, ESI†). After
removal of excess DIBO-Mal by Sephadex G-25 size-exclusion
chromatography with TBST0.05% as the mobile phase, the result-
ing nanoparticles (DIBO-Mal NPs) were then used for Michael
addition reactions with molecules bearing thiol groups. FGF2 has
previously been stoichiometrically conjugated to nanoparticles
via a N-terminal hexahistidine tag and its biological activity
correlated with its ability to bind to heparin.3,11,31 FGF2 possesses
two surface thiols, one of which is fully exposed (Fig. S4, ESI†).
FGF2 was incubated at 35 times molar excess over DIBO-Mal NPs
with mixing for 3 h on a rotating wheel. The mixture was then
purified by heparin agarose aﬃnity chromatography using
1 PBS with Tween-20 0.05% (v/v) (PBST0.05%) as the mobile
phase (Fig. 1). Nanoparticles bearing no maleimide functionality,
i.e., a mix matrix SAM, when incubated with FGF2 did not bind to
the column (Fig. 1a). This was also the case with DIBO-Mal NPs
(Fig. 1b). Moreover, when the DIBO-Mal NPs were incubated with
FGF2 protein that had its surface thiols blocked (by reaction with
and excess of biotin-maleimide), no nanoparticles bound to the
column (Fig. S5, ESI†). However, when the DIBO-Mal NPs were
incubated with FGF2 protein, the pink colour of the nano-
particles was seen on the heparin agarose column (Fig. 1c). The
nanoparticles were eluted with 2 M NaCl, as for native FGF2.3
Thus, the reaction of DIBO-Mal NPs with FGF2 protein only
proceeded via a thiol-Michael addition route.
We have shown previously that aﬃnity chromatography can
be used to evaluate the valency of functional nanoparticles.4
Particles that have one or more FGF2 proteins can be distin-
guished easily from those that have none by their capacity to
bind to heparin. Assuming a Poisson distribution for the
number of ligands per nanoparticle, we estimated that, when
10% of the nanoparticles were bound, the nanoparticle popula-
tion would possess an average of 0.1 functional ligands per
nanoparticle, which corresponds to 10% of the nanoparticles
possessing at least one functional ligand (with no more than
0.48% possessing two or more functional ligands) and 90% no
functional ligand.3,4 To demonstrate control over the number
of azide groups incorporated into the mix matrix SAM,
a titration was performed varying the molar percentage of azide
ligands (0–10%; mol/mol) in the ligand mix. The nanoparticles
Fig. 1 Purification of DIBO-FGF2 NPs by aﬃnity chromatography on
heparin agarose: (a) mix matrix nanoparticles with FGF2, (b) DIBO-Mal
NPs and (c) DIBO-Mal NPs with FGF2. Titration via heparin aﬃnity chroma-
tography of functional azide groups as molar% of ligand mixture (d and e).
Purification of dp12 oligosaccharide nanoparticle conjugates using anion
exchange chromatography on DEAE-Sepharose: (f) mix matrix nano-
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were reacted with a 35-fold molar excess of FGF2 protein for
3 h. Heparin affinity chromatography was used to determine
the number of FGF2 functionalised nanoparticles, and thereby
the number of azide groups reacted with DIBO-Mal per nano-
particle (Fig. 1d). The nanoparticles that do not bind, and are
present in the flow through are those lacking an azide group or
those that failed to react with DIBO-MAL. From the flow
through the concentration of nanoparticles bound to the
heparin affinity column was quantified by UV-vis spectro-
metry32 (Fig. 1e). The percentage of nanoparticles bound to
the heparin column increased as the mol% of N3 ligand
increased (Fig. 1e). No binding was observed in the absence
of azide ligand (Fig. 1d). The concentration at which 10% of the
nanoparticles bound to the heparin column was a molar ratio
of 0.28% (mol/mol) azide ligand to matrix ligands (Fig. 1h).
From this point, to prepare monovalent maleimide function-
alised nanoparticles, the initial N3NPs were synthesized with
0.28% (mol/mol) azide ligand in their monolayer. It is impor-
tant to note that this titration may hold for the current batches
of ligands and nanoparticles. Different batches have differences
in, e.g., peptidol purity, nanoparticle size, so the titration curve
will be shifted.
To demonstrate the versatility of maleimide functionalised
nanoparticles, advantage was taken of the resistance of the mix
matrix ligand shell to DTT induced ligand exchange (Fig. S2,
ESI†). This would allow the DIBO-Mal NPs to be reacted with
dithiols, e.g., dithiothreitol (DTT) to yield a thiol-functionalised
nanoparticle (SH NP; Fig. S6, ESI†) that can be reacted with a
maleimide functionalised biological molecule. To this end we
used a heparin-derived oligosaccharide (degree of polymerisation
(dp)12), possessing a reducing-end maleimide function, dp12-Mal
(Fig S6, ESI†). The dp12 oligosaccharide for the reaction was
generated via the digestion and purification of porcine mucosal
heparin (Celsus Laboratories, Cincinati, OH, USA; compound
purity Table S1 and NMR characterisation Table S2, ESI†).33
A Schiﬀ base reaction with 2 mg of freeze-dried dp12 and
100 mL of 15 mg mL1 4-(4-N-maleimidophenyl)butyric acid
hydrazide-HCl (MPBH; Thermo Fischer Scientific Inc., Rock-
ford, IL, USA) was performed. This provided the means to
couple sugars with a reducing end to the maleimide.34 The
dp12-Mal product was then purified via anion-exchange chro-
matography on a Hi-Trap Q column (Fig. S7, ESI†). A clear peak
was observed at 35 min, with absorbance at 230 nm owing to
the chromophore within the MPBH structure (Fig. S7, ESI†).
To install a thiol on the surface of the nanoparticles,
DIBO-Mal NPs were incubated with 1 mM DTT for 1 hour, after
which excess DTT was removed via Sephadex G-25 size-exclusion
chromatography with PBST0.05% as the mobile phase. The nano-
particles were then reacted with dp12-Mal. Chromatography
of the mixture on an anion-exchange resin, DEAE-Sepharose,
to which the dp12 binds, was used to determine the presence
of oligosaccharides on the nanoparticle with PBST0.05% as the
mobile phase. Nanoparticles with a non-functionalised mix
monolayer incubated with oligosaccharide dp12 did not bind
to the DEAE-Sepharose (Fig. 1f) and neither did SH NPs (Fig. 1g).
However, when SH NPs had been incubated with the dp12 they
bound to the DEAE-Sepharose, indicated by a pink colour at the
top of the column (Fig. 1h). Thus, nanoparticles only bind to the
resin when the Michael addition reaction has occurred between
SH NPs and the maleimide modified oligosaccharides. The
nanoparticles functionalised with maleimide-modified dp12
were eluted from the DEAE resin using 2 M NaCl.
In summary, we have demonstrated control over the number
of maleimide groups down to monovalency into a monolayer
that is resistant to ligand exchange via copper-free click chemi-
stry. These nanoparticles provide a platform for the successful
covalent conjugation of FGF2 protein, the installation of a thiol
functional group on the nanoparticles and reaction with a
maleimide functionalised oligosaccharide, dp12-Mal, via Michael
addition reactions. With the control over the number of maleimide
groups on the nanoparticle established, these nanoparticle con-
jugates are stoichiometrically coupled at a ratio of one nano-
particle to one biological molecule. DIBO-Mal NPs show great
potential for the covalent labelling of biomolecules, or even other
nanomaterials, that can undergo Michael addition reactions.
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